Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$11.85
-0.05 (-0.42%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-17.2M · quality 61.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$427M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-17.6%
↓Gross Margin
53.4%
↑Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.6%
FCF CAGR
—
FCF margin
-43.6%
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $88.4M · net income $-40.5M · FCF $-38.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $88.4M | $88.4M | $93.5M | $103.2M | $128.1M |
| Net Income | $-40.5M | $-40.5M | $-24.8M | $-21.8M | $-6.4M |
| EBITDA | $-33.4M | $-33.4M | $-17.7M | $-16.3M | $-1.5M |
| EPS | — | — | -0.70 | -0.61 | -0.18 |
| Gross Margin | 53.4% | 53.4% | 52.1% | 49.4% | 58.2% |
| Operating Margin | -49.9% | -49.9% | -33.0% | -26.5% | -16.3% |
| Net Margin | -45.8% | -45.8% | -26.6% | -21.1% | -5.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.05 | 0.00 | 0.01 |
| Current Ratio | 4.86 | 4.86 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-38.6M | $-38.6M | $-17.2M | $3.9M | $-32.1M |
| Returns | |||||
| ROE | -17.6% | -17.6% | -8.7% | -7.0% | -2.1% |
| Valuation | |||||
| P/B | 1.83 | 1.83 | 1.75 | 1.66 | 1.71 |
| Growth & Yield | |||||
| Revenue Growth | -5.4% | -5.4% | -9.5% | -19.4% | — |
| EPS Growth | — | — | -14.8% | -238.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.70 → n/d
Residual
-15.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.